Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Free Cash Flow (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of Free Cash Flow data on record, last reported at $26.2 million in Q4 2025.

  • For Q4 2025, Free Cash Flow rose 3600.67% year-over-year to $26.2 million; the TTM value through Dec 2025 reached -$6.3 million, up 94.38%, while the annual FY2025 figure was -$6.3 million, 94.38% up from the prior year.
  • Free Cash Flow reached $26.2 million in Q4 2025 per ARQT's latest filing, up from -$1.8 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $26.2 million in Q4 2025 and bottomed at -$80.4 million in Q1 2023.
  • Average Free Cash Flow over 5 years is -$40.0 million, with a median of -$44.6 million recorded in 2023.
  • Peak YoY movement for Free Cash Flow: tumbled 122.11% in 2021, then soared 3600.67% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$52.0 million in 2021, then tumbled by 36.98% to -$71.2 million in 2022, then grew by 20.98% to -$56.2 million in 2023, then surged by 98.67% to -$748000.0 in 2024, then skyrocketed by 3600.67% to $26.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were $26.2 million in Q4 2025, -$1.8 million in Q3 2025, and $246000.0 in Q2 2025.